About Aurigene
Aurigene is committed to accelerating access to affordable and innovative medicines, driven by the belief that good health can't wait. With over 20 years of experience, we offer integrated services across drug discovery, development, and manufacturing (CRDMO) for small molecule and biologics. Our expertise encompasses for Biologics and small molecule, along with peptides, pegylated drugs, steroids, high-potency APIs, and flow chemistry, all backed by advanced technology platforms.
At Aurigene biologics, we deliver a truly end-to-end service offering, from discovery services through CMC process development, clinical scale cGMP manufacture to large scale commercial manufacture of both drug substance and drug product from state-of-the-art facilities inspected by US FDA, EMA, MHRA and dozens of other regulatory authorities. We work with companies around the globe to accelerate their programs.
Meet our CRDMO experts
We are proud of our world-class team of Europe-based professionals, each bringing extensive expertise in drug discovery, development and manufacturing. With in-depth knowledge of the pharmaceutical and biotech sectors, our experts are dedicated to helping you achieve your drug innovation goals with efficiency and precision.
Kapil Chowdhury
Global Head, Buisness Development
Tania Dey
Director, Business Development
Kapil Chowdhury
Global Head, Buisness Development
Ashwini Kapoor
Director, Business Development
Raj Sharma
Director, Business Development
Akshay Ranjan Shukla
Sr. Director, Business Development
Why Aurigene Pharmaceutical Services?
20+
years’ experience
900+
scientists
125+
global clients
600+
projects
19
NCEs
commercialized
16
USFDA inspected
cGMP facilities
6
Biologics
commercialized
3
manufacturing countries
UK, Mexico, India
In the discovery space, Aurigene boasts a legacy of more than 25 years of operations and has long-term partnerships with two of the top five pharmaceutical companies. We offer chemistry, biology, and integrated services across the life cycle of drug discovery, from target identification to IND filing. We operate in a flexible manner and offer our services in FTE and/or FFS mode; integrated and/or standalone mode.
Chemistry
Biology
FormulationsAurigene Facilities Location
Hyderabad:
Aurigene Pharmaceutical Services Limited,
Bollaram Road, Miyapur, Jaya Prakash Narayan Nagar, Miyapur, Telangana 500049
Bangalore:
Aurigene Pharmaceutical Services Limited,
39- 40 Hosur Road KIADB Industrial Area, Joggers Ln, Phase 2, Electronic City, Bengaluru, Karnataka 560100
Visakhapatnam:
APIIC Industrial Estate, Pydibhimavarama (village), Srikakulam district, Andhra Pradesh, India.
UK: API/ RSM Manufacturing Plant
Steanard Ln, Mirfield W 14 8HZ, United Kingdom
Mexico:
C.P, Carretera Federal Cuernavaca-Cuautla Km. 4. 5 Colonia CIVAC Jiutepec, 62578 Cuernavaca, Mor. Mexico
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Learning Resources
Transforming Drug Discovery with Aurigene.AI
In the early 2000s, developing Sovaldi, a hepatitis C treatment, took over a decade and nearly $2 billion. Similarly, Zolgensma, a gene therapy for spinal muscular atrophy, required 15 years due to its complexity. However, the advent of artificial intelligence (AI) has revolutionized drug discovery. For example, in 2022, Pfizer's PAXLOVID, an oral COVID-19 treatm...
Read More
Advancement in personalized medicine and how the CRDMO industry is part of the solution
Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role in enabli...
Read More
Overcoming challenges with cyclic peptides for In-vitro experiments and Bioanalysis
Project Requirement:Cyclic peptides were to be analyzed for Kinetic solubility, Chrom Log D, MDCK, PAMPA, & Caco2 experiments, while overcoming the challenges associated with the impact of cyclization of peptides on in vitro experiments and bioanalysisWhat were the challenges!1. Nonspecific Binding (NSB)2. Precipitation of peptides while spiking DMSO stock to...
Read More
Development and assessment of a Bcs class II - SGLT2 (Sodium Glucose Cotransporter 2) inhibitor drug in the form of solid lipid Nanoparticles by selecting different lipids, co-surfactants, and manufacturing techniques
2025
Drug Delivery System (DDS) has been used successfully in the past few decades to cure illnesses and enhance health because of its improved systemic circulation and ability to regulate the drug's pharmacological action. As pharmacology and pharmacokinetics advanced, the idea of controlled release emerged, demonstrating the significance of drug release in assessing...
Read More-
Development of novel paullone-based PROTACs as anticancer agents
2025
Proteolysis-targeting chimera (PROTACs) represents a promising modality that has gained significant attention for cancer treatment. Using PROTAC technology, we synthesized novel structurally modified paullone-based PROTACs using Cereblon (CRBN) and Von Hippel–Lindau (VHL) E3 ligands....
Read More -
Development and verification of RP-HPLC method for the quantitative determination of Decitabine in tablet dosage formulation
2025
Decitabine is an anti-cancer chemotherapy drug. This article describes method development and method verification of Assay of Decitabine in tablet formulation. A new, precise, rapid, accurate RP-HPLC method has been developed for the estimation of Decitabine in pharmaceutical tablets dosage form. After optimization the good chromatographic separation was achieved...
Read More -
A simple RP-HPLC method development and verification of the Dissolution of Bromelain-A Complex mixture of proteolytic enzymes, in delayed release tablets
2024
Bromelain is a complex natural mixture of proteolytic enzymes derived from pineapple (Ananas cosmosus), which has good therapeutic properties. Bromelain can be found in all tissues of pineapple plants, including the stem, fruit, and leaves. Bromelain plays an important role in the treatment of many diseases such as soft tissue inflammation and edema, deep derma, ...
Read More
Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx announce potential partnership for joint development of affordable anti-malarial drug
2024
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), and its CRDMO arm Aurigene Pharmaceutical Services Limited (Aurigene), today announced that they have signed a non-binding Memorandum of Understanding (MoU) with Kainomyx, Inc., a US-based company with ...
Read More-
Aurigene Pharmaceutical Services Limited, a global CRDMO, and Edity announce a strategic collaboration in cell therapy
2024
Aurigene Pharmaceutical Services Limited (Aurigene), a global contract research, development, and manufacturing services organization (CRDMO), will provide discovery services to Edity Therapeutics Limited (Edity) in cell therapy. Dr. Reddy’s Laboratories Limited, Aurigene’s parent company, recently made a strategic investment in Edity, a biotechnology company...
Read More -
Aurigene Pharmaceutical Services Limited, a global CRDMO, announces the opening of its biologics facility offering process development and clinical scale manufacturing capabilities
2024
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with process & analytical development and small scale manufacturing of antibodies and o...
Read More -
Aurigene Pharmaceutical Services Ltd., and Vipergen announce a strategic partnership for offering DNA encoded library (DEL) screening and integrated drug discovery services
2024
Aurigene Pharmaceutical Services Ltd. (Aurigene), a global contract research, development, and manufacturing services organization (CRDMO), and Vipergen ApS, a niche small-molecule drug discovery service provider specialized in DEL technologies, entered into a strategic partnership....
Read More
CPHI Japan
Tokyo, Japan
09-11 April, 2025
-
DCAT Week 2025
Lotte New York Palace, 455 Madison Avenue, at 50th Street, New York NY - 10022
17-20 March, 2025
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market